מרץ 2023

רופא/ה נכבד/ה,
רוקח/ת נכבד/ה,

הנדון:
Xarelto 15mg, Xarelto 20mg
קסרלטו 15מ"ג, קסרלטו 20מ"ג
Film coated tablets
Rivaroxaban

חברת באייר מתכבדת להודיע כי העלונים לרופא ולצרכן לתכשירים שבנדון עודכנו.

התוויות מאושרות:

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

בהודעה זו כלולים העידכונים המהותיים בלבד. בפירוט שלהלן מופיע, מתוך כל פרק ששונה בעלונים, רק המידע שהתעדכן. תוספת טקסט מסומנת בקו תחתון, מחיקת טקסט מסומנת ~~בקו חוצה~~.

העדכונים בעלון לרופא:

…
4.8 Undesirable effects
…
Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies

Indication	**Number of patients***	**Total daily dose**	**Maximum treatment duration**
…			
Prevention of atherothrombotic events in patients with CAD/PAD	18,244	5 mg co-administered with ASA or 10 mg alone	47 months
	3,256**	5 mg co-administered with ASA	42 months

*Patients exposed to at least one dose of rivaroxaban
** From the VOYAGER PAD study
...

Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies

Indication	Any bleeding	Anaemia
…		
Prevention of atherothrombotic events in patients with CAD/PAD	6.7 per 100 patient years	0.15 per 100 patient years**
	8.38 per 100 patient years #	0.74 per 100 patient years*** #

* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.
** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied
*** A selective approach to adverse event collection was applied
# From the VOYAGER PAD study

Tabulated list of adverse reactions
…

Table 3: All adverse reactions reported in patients in phase III clinical studies or through post-marketing use*

Common	Uncommon	Rare	Very rare	Not known
…				
Respiratory, thoracic and mediastinal disorders				
Epistaxis, haemoptysis			Eosinophilic pneumonia	
…				

…
4.9 Overdose
…
A specific reversal agent (andexanet alfa) ~~antidote~~ antagonising the pharmacodynamic effect of rivaroxaban is ~~not~~ available (refer to the physician prescribing information of andexanet alfa).The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.

Management of bleeding
…
If bleeding cannot be controlled by the above measures, either the administration of a specific factor Xa inhibitor reversal agent (andexanet alfa), which antagonises the pharmacodynamic effect of rivaroxaban, or ~~administartion of~~ a specific procoagulant ~~reversal~~ agent, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa), should be considered.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

…

Clinical efficacy and safety

Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation

…

In a post-authorisation, non-interventional study, in more than 162,000 patients from four countries, rivaroxaban was prescribed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The event rate for ischaemic stroke was 0.70 (95% CI 0.44 - 1.13) per 100 patient-years. Bleeding resulting in hospitalisation occurred at event rates per 100 patient-years of 0.43 (95% CI 0.31 - 0.59) for intracranial bleeding, 1.04 (95% CI 0.65 - 1.66) for gastrointestinal bleeding, 0.41 (95% CI 0.31 - 0.53) for urogenital bleeding and 0.40 (95% CI 0.25 - 0.65) for other bleeding.

…

Treatment of DVT, PE and prevention of recurrent DVT and PE

…

In a post-authorisation, non-interventional study, in more than 40,000 patients without a history of cancer from four countries, rivaroxaban was prescribed for the treatment or prevention of DVT and PE. The event rates per 100 patient-years for symptomatic/clinically apparent VTE/thromboembolic events leading to hospitalisation ranged from 0.64 (95% CI 0.40 - 0.97) in the UK to 2.30 (95% CI 2.11 - 2.51) for Germany. Bleeding resulting in hospitalisation occurred at event rates per 100 patient-years of 0.31 (95% CI 0.23 - 0.42) for intracranial bleeding, 0.89 (95% CI 0.67 - 1.17) for gastrointestinal bleeding, 0.44 (95% CI 0.26 - 0.74) for urogenital bleeding and 0.41 (95% CI 0.31 - 0.54) for other bleeding.

…

העדכונים בעלון לצרכן:

4) תופעות לוואי

...

תופעות לוואי נוספות

...

תופעות לוואי נדירות מאוד (Very rare) (תופעות שעלולות להשפיע על עד משתמש אחד מתוך 10,000):

- הצטברות של אאוזינופילים, סוג של תאי דם גרנולוציטיים לבנים הגורמים לדלקת בריאות (דלקת ריאות אאוזינופילית).

...

העלון לרופא ולצרכן נשלחו לפרסום במאגר התרופות שבאתר משרד הבריאות:
https://israeldrugs.health.gov.il/

ניתן לקבלם מודפסים ע"י פניה לחברת באייר ישראל, רח' החרש 36 הוד השרון, טלפון: 09-7626700.

בברכה,

באייר ישראל